BioNexus Gene Lab Corp - FORM 10-Q

Attached files

file	filename
EX-32.1 - CERTIFICATION - BioNexus Gene Lab Corp	bion_ex321.htm
EX-31.2 - CERTIFICATION - BioNexus Gene Lab Corp	bion_ex312.htm
EX-31.1 - CERTIFICATION - BioNexus Gene Lab Corp	bion_ex311.htm

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2021

☐ TRANSACTION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____________

Commission File Number: 333-229399

BIONEXUS GENE LAB CORP.

(Exact name of registrant as specified in its charter)

Wyoming		35-2604830
(State or Other Jurisdiction of Incorporation or Organization)		(I.R.S. Employer Identification No.)

Unit 02, Level 10 Tower B, Avenue 3, The Vertical Business Suite II Bangsar South No. 8 Jalan Kerinchi Kuala Lumpur, Malaysia		59200
(Address of Principal Executive Offices)		(Zip Code)

+60 1221-26512

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act: None

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer, ” “ accelerated filer, ” “non-accelerated filer ,” “ smaller reporting company, ” and “ emerging growth company ” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of April 30, 2021, there were 171,218,152 shares of common stock, no par value, outstanding.

TABLE OF CONTENTS

		Page
PART I – FINANCIAL INFORMATION

Item 1.	Financial Statements	3
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	24
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	33
Item 4.	Controls and Procedures	33

PART II – OTHER INFORMATION

Item 1.	Legal Proceedings	36
Item 1A.	Risk Factors	36
Item 2.	Unregistered Sale of Equity Securities and Use of Proceeds	36
Item 3.	Defaults Upon Senior Securities	36
Item 4.	Mine Safety Disclosures	36
Item 5.	Other Information	36
Item 6.	Exhibits	37

SIGNATURES		38

Table of Contents

PART I — FINANCIAL INFORMATION

ITEM 1. Financial Statements

BIONEXUS GENE LAB CORP.

CONDENSED CONSOLIDATED BALANCE SHEETS

AS OF MARCH 31, 2021 AND DECEMBER 31, 2020

(Currency expressed in United States Dollars (“US$”))

		As of
		March 31,		December 31,
	Note	2021		2020
		(Unaudited)		(Audited)
ASSETS
CURRENT ASSETS
Cash and bank balances			853,198		699,585
Fixed deposits placed with financial institutions			1,621,461		2,088,107
Trade receivables	4		3,593,663		3,996,802
Other receivables, deposits and prepayments			22,933		22,640
Tax Recoverable	5		2,624		2,190
Inventories			1,469,192		1,176,170
Total current assets			7,563,071		7,985,494

NON-CURRENT ASSETS
Operating lease right of use asset, net	6		55,747		62,529
Property, plant and equipment, net	7		1,708,104		1,785,602
Other investments	8		571,609		281,668
Total non-current assets			2,335,460		2,129,799
TOTAL ASSETS		$	9,898,531	$	10,115,293

LIABILITIES AND STOCKHOLDERS’ EQUITY
CURRENT LIABILITIES
Trade payables	9		2,928,650		3,170,653
Other payables and accrued liabilities			38,269		95,882
Current portion of obligation under finance lease	10		22,843		25,048
Current portion of operating lease liabilities	6		16,793		20,702
Tax payables	5		28,874		61,313
Total current liabilities			3,035,429		3,373,598

Table of Contents

PART I — FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS (CONT’D)

BIONEXUS GENE LAB CORP.

CONDENSED CONSOLIDATED BALANCE SHEETS

AS OF MARCH 31, 2021 AND DECEMBER 31, 2020

(Currency expressed in United States Dollars (“US$”))

		As of
NON-CURRENT LIABILITIES	Note	March 31, 2021 (Unaudited)			December 31, 2020 (Audited)
Non-current portion of operating lease liabilities	6		39,911			42,377
Non-current portion of obligation under finance lease	10		28,948			35,292
Deferred tax liabilities	5		1,813			1,872
Total non-current liabilities			70,672			79,541
TOTAL LIABILITIES		$	3,106,101		$	3,453,139

STOCKHOLDERS’ EQUITY
As at March 31, 2021, common stock, no par value; 300,000,000 shares authorized and 171,218,152 shares outstanding, and preferred stock, no par value; 30,000,000 shares authorized and no shares outstanding. As at December 31, 2020, common stock, no par value; 300,000,000 shares authorized and 171,218,152 shares outstanding, and preferred stock, no par value; 30,000,000 shares authorized and no shares outstanding.	11		10,779,574			10,779,574
Additional paid in capital			(5,011,891	)		(5,011,891	)
Accumulated surplus			1,099,531			760,787
Other comprehensive (losses) /income			(74,784	)		133,684
TOTAL STOCKHOLDERS’ EQUITY			6,792,430			6,662,154

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY		$	9,898,531		$	10,115,293

See accompanying notes to the condensed consolidated financial statements.

Table of Contents

BIONEXUS GENE LAB CORP.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

FOR THE THREE MONTHS ENDED MARCH 31, 2021 AND 2020

(Currency expressed in United States Dollars (“US$”))

(Unaudited)

	Three months ended
	March 31,
	2021			2020

REVENUE	$	3,449,159		$	3,070,026

COST OF REVENUE		(2,866,594	)		(2,414,719	)

GROSS PROFIT		582,565			655,307

OTHER INCOME		62,388			746,641

OPERATING EXPENSES
General and administrative		(302,851	)		(328,418	)

PROFIT FROM OPERATIONS		342,102			1,073,530

FINANCE COSTS		(3,358	)		(3,026	)

PROFIT BEFORE TAX		338,744			1,070,504

Tax expense		0			(860	)

NET PROFIT	$	338,744		$	1,069,644

Other comprehensive income:
Foreign currency translation loss		(208,468	)		(294,696	)

COMPREHENSIVE INCOME	$	130,276		$	774,948

Earnings per share - Basic and diluted		0			0

Weighted average number of common shares outstanding – Basic and diluted		171,218,152			102,730,891

See accompanying notes to the condensed consolidated financial statements.

Table of Contents

BIONEXUS GENE LAB CORP
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY
AS OF MARCH 31, 2021 AND 2020
(Amount expressed in United States Dollars (“US$))

	Common stock				Additional						Accumulated other comprehensive
	Number of shares		Amount		paid in capital			Accumulated surplus/(loss)			income/ (loss)			Total Equity
Balance as of January 1, 2020		102,730,891	$	6,484,669	$	(5,011,891	)	$	(333,311	)	$	(17,103	)	$	1,122,364
Issuance of shares		68,487,261		4,294,905		-			-			-			4,294,905
Net profit for the period		-		-		-			1,069,644			-			1,069,644
Foreign currency translation gain		-		-		-			-			(294,696	)		(294,696	)
Balance as of March 31, 2020		171,218,152	$	10,779,574	$	(5,011,891	)	$	736,333		$	(311,799	)	$	6,192,217

Balance as of December 31, 2020		171,218,152	$	10,779,574	$	(5,011,891	)	$	760,787		$	133,684		$	6,662,154
Net profit for the period		-		-		-			338,744			-			338,744
Foreign currency translation loss
		-		-		-			-			(208,468	)		(208,468	)
Balance as of March 31, 2021		171,218,152	$	10,779,574	$	(5,011,891	)	$	1,099,531		$	(74,784	)	$	6,792,430

See accompanying notes to the condensed consolidated financial statements.

Table of Contents

BIONEXUS GENE LAB CORP.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE THREE MONTHS ENDED MARCH 31, 2021 AND 2020

(Currency expressed in United States Dollars (“US$”))

(Unaudited)

	Three months ended
	March 31,
	2021			2020
Cash flows from operating activities:
Net profit	$	338,744		$	1,069,644

Adjustments to reconcile net profit to net cash generated from operating activities:
Amortization of right of use asset		4,434			2,865
Depreciation of property, plant and equipment		10,622			10,278
Dividend income		(1,006	)		(179	)
Fair value gain on other investments		(8,264	)		-
Gain on disposal of property, plant and equipment		-			(710,172	)
Operating profit before working capital changes		344,530			372,436

Changes in operating assets and liabilities:
Inventories		(293,022	)		1,258
Trade and other receivables		402,845			163,791
Trade and other payables		(299,619	)		(1,470,936	)
Operating lease liabilities		(6,375	)		(3,944	)
Tax recoverable		(32,931	)		(39,953	)
Cash generated from/(used in) operating activities		115,428			(977,348	)

Cash flows from investing activities:
Acquisition of other investment		(296,025	)		(101,498	)
Dividend income		1,006			179
Net cash from acquisition of business under common control		-			346,008
Purchase of plant and equipment		(807	)		(307	)
Proceeds from disposal of property, plant and equipment		-			1,467,865
Net cash (used in)/ generated from investing activities		(295,826	)		1,712,247

Cash flows from financing activities:
Repayment of finance lease		(8,550	)		(6,399	)
Net cash used in from financing activities		(8,550	)		(6,399	)

Table of Contents

ITEM 1. FINANCIAL STATEMENTS (CONT’D)

BIONEXUS GENE LAB CORP.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE THREE MONTHS ENDED MARCH 31, 2021 AND 2020

(Currency expressed in United States Dollars (“US$”))

(Unaudited)

	Three months ended
	March 31,
	2021			2020

Foreign currency translation adjustment		(124,085	)		(190,829	)
NET CHANGE IN CASH AND CASH EQUIVALENTS		(313,033	)		537,671
CASH AND CASH EQUIVALENTS, BEGINNING OF FINANCIAL YEAR		2,787,692			859,076

CASH AND CASH EQUIVALENTS, END OF FINANCIAL YEAR	$	2,474,659		$	1,396,747

CASH AND CASH EQUIVALENTS INFORMATION:
Fixed deposits placed with financial institutions	$	1,621,461		$	503,188
Cash at bank		853,198			893,559
Cash and cash equivalents, end of financial year		2,474,659			1,396,747

Supplementary cash flow information:
Interest paid	$	(3,358	)	$	(3,026	)
Income taxes paid		(36,438	)		(57,069	)

See accompanying notes to the condensed consolidated financial statements.

Table of Contents

BIONEXUS GENE LAB CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED MARCH 31, 2021

(Currency expressed in United States Dollars (“US$”))

(Unaudited)

NOTE 1 - BASIS OF PREPARATION

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial reporting and the rules and regulations of the Securities and Exchange Commission that permit reduced disclosure for interim periods. Therefore, certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted.

In the opinion of management, the consolidated balance sheet as of March 31, 2021 which has been derived from unaudited financial statements and these unaudited condensed consolidated financial statements reflect all normal and recurring adjustments considered necessary to state fairly the results for the periods presented. The results for the three months ended March 31, 2021 are not necessarily indicative of the results to be expected for the entire fiscal year ending December 31, 2021 or for any future period.

These unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the Management’s Discussion and the audited financial statements and notes thereto included in the Annual Report on Form 10-K for the fiscal year ended December 31, 2020.

NOTE 2 - ORGANIZATION AND BUSINESS BACKGROUND

BioNexus Gene Lab Corp. was incorporated in the State of Wyoming on May 12, 2017. On August 23, 2017, the Company acquired all of the outstanding capital stock of Bionexus Gene Lab Sdn. Bhd., a Malaysian corporation (“Subsidiary”). The Subsidiary was incorporated in Malaysia on April 7, 2015 which it then subsequently changed its name to Bionexus Gene Lab Sdn. Bhd.

On December 31, 2020, the Company consummated a Share Exchange Agreement with Chemrex Corporation Sdn. Bhd. (“Chemrex”) and the Chemrex shareholders pursuant to which we acquired all of the issued and outstanding shares of capital stock of Chemrex from the Chemrex shareholders in exchange for 68,487,261 shares of common stock of the Company issued to the Chemrex shareholders.

The acquisition of Chemrex has been accounted for as a common control transaction as there is no change in the control over the assets acquired and liabilities assumed. The net assets are derecognized by the transferring entity (i.e. Chemrex) and recognized by the receiving entity (i.e. the Company). The difference between the consideration transferred and the carrying amounts of the net assets is recognized in equity.

The principal office address is Unit 02 Level 10, Tower B, Vertical Business Suite, No. 8 Jalan Kerinchi, Bangsar South, 59200 Kuala Lumpur, Malaysia, our lab is located at Lab 353, Chemical Science Centre, University Science Malaysia, George Town, Penang, Malaysia. We also have a blood collection center located at 1st floor, Lifecare Medical Centre, Kuala Lumpur, Malaysia. Chemrex offices and supply hub is located at 4 Jalan CJ 1/6 Kawasan Perusahaan Cheras Jaya, Selangor, Malaysia.

Table of Contents

BIONEXUS GENE LAB CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED MARCH 31, 2021

(Currency expressed in United States Dollars (“US$”))

(Unaudited)

The financial statements of the receiving entity report the results of operations for the period in which the transfer occurs as though the transfer of net assets or exchange of equity interests had occurred at the beginning of the period. Results of operations for that period will thus comprise those of the previously separate entities combined from the beginning of the period to the date the transfer is completed and those of the combined operations from that date to the end of the period. The comparative financial statements were not adjusted retrospectively as Chemrex Corporation Sdn. Bhd. was not under common control during the comparative period.

The corporate structure as at March 31, 2021 is depicted below:

NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The accompanying unaudited condensed consolidated financial statements reflect the application of certain significant accounting policies as described in this note and elsewhere in the accompanying consolidated financial statements and notes.

•	Basis of presentation

The accompanying condensed consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”).

•	Basis of consolidation

The condensed consolidated financial statements include the accounts of Bionexus Gene Lab Corp. and its subsidiaries. All significant inter-company balances and transactions within the Company have been eliminated upon consolidation.

•	Use of estimates

In preparing these condensed consolidated financial statements, management makes estimates and assumptions that affect the reported amounts of assets and liabilities in the balance sheets and revenues and expenses during the periods reported. Actual results may differ from these estimates.

Table of Contents

BIONEXUS GENE LAB CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED MARCH 31, 2021

(Currency expressed in United States Dollars (“US$”))

(Unaudited)

•	Cash and cash equivalents

Cash and cash equivalents represent cash on hand, demand deposits placed with banks or other financial institutions and all highly liquid investments with an original maturity of three months or less as of the purchase date of such investments.

•	Trade receivables

Trade receivables are recorded at the invoiced amount and do not bear interest. Management reviews the adequacy of the allowance for expected credit losses on an ongoing basis, using historical collection trends and aging of receivables. Management also periodically evaluates individual customer’s financial condition, credit history, and the current economic conditions to make adjustments in the allowance when it is considered necessary. Trade balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote.

•	Inventories

Inventories consisting of products available for sell, are stated at the lower of cost or market value. Cost of inventory is determined using the first-in, first-out (FIFO) method. Inventory reserve is recorded to write down the cost of inventory to the estimated market value due to slow-moving merchandise and damaged goods, which is dependent upon factors such as historical and forecasted consumer demand, and promotional environment. The Company takes ownership, risks and rewards of the products purchased. Write downs are recorded in cost of revenues in the Statement of Operations and Comprehensive Income

•

Leases

In February 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2016-02, Leases, which was subsequently amended in 2018 by ASU 2018-10, ASU 2018-11 and ASU 2018-20 (collectively, Topic 842). Topic 842 will require the recognition of a right-of-use asset and a corresponding lease liability, initially measured at the present value of the lease payments, for all leases with terms longer than 12 months. For operating leases, the asset and liability will be expensed over the lease term on a straight-line basis, with all cash flows included in the operating section of the statement of cash flows. For finance leases, interest on the lease liability will be recognized separately from the amortization of the right-of-use asset in the statement of comprehensive income and the repayment of the principal portion of the lease liability will be classified as a financing activity while the interest component will be included in the operating section of the statement of cash flows. Topic 842 is effective for annual and interim reporting periods beginning after December 15, 2018. Early adoption is permitted. Upon adoption, leases will be recognized and measured at the beginning of the earliest period presented using a modified retrospective approach. Topic 842 allows for a cumulative-effect adjustment in the period the new lease standard is adopted and will not require restatement of prior periods.

Table of Contents

BIONEXUS GENE LAB CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED MARCH 31, 2021

(Currency expressed in United States Dollars (“US$”))

(Unaudited)

Prior to January 1, 2019, the Company accounted for leases under ASC 840, Accounting for Leases. Effective January 1, 2019, the Company adopted the guidance of ASC 842, Leases, which requires an entity to recognize a right-of-use asset and a lease liability for virtually all leases. The Company adopted ASC 842 using a modified retrospective approach. As a result, the comparative financial information has not been updated and the required disclosures prior to the date of adoption have not been updated and continue to be reported under the accounting standards in effect for those periods.

•	Property, plant and equipment

Property, plant and equipment are stated at cost less accumulated depreciation and accumulated impairment losses, if any. Depreciation is calculated on the straight-line basis to write off the cost over the following expected useful lives of the assets concerned.

The principal annual rates used are as follows:

Categories			Principal Annual Rates
Air conditioner			20%
Buildings			2%
Computer and software			33%
Equipment			20%
Furniture and fittings			10% to 20%
Lab Equipment			10%
Motor vehicle			10% to 20%
Office equipment			20%
Renovation			10% to 20%
Signboard			10%

Leasehold lands are depreciated over the period of lease term. Leased assets are depreciated over the shorter of the lease term and their useful lives unless it is reasonably certain that the Company will obtain ownership by the end of the lease term. Freehold land is not depreciated. Property, plant and equipment under construction are not depreciated until the assets are ready for their intended use

Maintenance and repairs are charged to operations as incurred. Expenditures which substantially increase the useful lives of the related assets are capitalized. When properties are disposed of, the related costs and accumulated depreciation are removed from the accounts and any gain or loss is reported in the period the transaction takes place.

Fully depreciated plant and equipment are retained in the financial statements until they are no longer in use.

Table of Contents

BIONEXUS GENE LAB CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED MARCH 31, 2021

(Currency expressed in United States Dollars (“US$”))

(Unaudited)

•	Impairment of long-lived assets

Long-lived assets primarily include goodwill, intangible assets and property, plant and equipment. In accordance with the provision of ASC Topic 360, “Impairment or Disposal of Long-Lived Assets”, the Company generally conducts its annual impairment evaluation to its long-lived assets, usually in the fourth quarter of each fiscal year, or more frequently if indicators of impairment exist, such as a significant sustained change in the business climate. The recoverability of long-lived assets is measured at the lowest level group. If the total of the expected undiscounted future net cash flows is less than the carrying amount of the asset, a loss is recognized for the difference between the fair value and carrying amount of the asset. There has been no impairment charge for the years presented.

•	Revenue recognition

Revenues are recognized when control of the promised goods or services are transferred to a customer, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services.

The Company applies the following five steps in order to determine the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements:

·	identify the contract with a customer;

·	identify the performance obligations in the contract;

·	determine the transaction price;

·	allocate the transaction price to performance obligations in the contract; and

·	recognize revenue as the performance obligation is satisfied.

The Company records revenue at point in time which is recognized upon goods delivered or services rendered.

•	Cost of revenues

Cost of revenue includes the purchase cost of retail goods for re-sale to customers and packing materials (such as boxes). It excludes purchasing and receiving costs, inspection costs, warehousing costs, internal transfer costs and other costs of distribution network in cost of revenues.

Table of Contents

BIONEXUS GENE LAB CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED MARCH 31, 2021

(Currency expressed in United States Dollars (“US$”))

(Unaudited)

•	Comprehensive income

ASC Topic 220, “Comprehensive Income” establishes standards for reporting and display of comprehensive income, its components and accumulated balances. Comprehensive income as defined includes all changes in equity during a period from non-owner sources. Accumulated other comprehensive income, as presented in the accompanying statements of stockholders’ equity consists of changes in unrealized gains and losses on foreign currency translation and cumulative net change in the fair value of available-for-sale investments held at the balance sheet date. This comprehensive income is not included in the computation of income tax expense or benefit.

•	Income taxes

Income taxes are determined in accordance with the provisions of ASC Topic 740, “Income Taxes” (“ASC Topic 740”). Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted income tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Any effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

The Company conducts major businesses in Malaysia and is subject to tax in their own jurisdictions. As a result of its business activities, the Company will file separate tax returns that are subject to examination by the foreign tax authorities.

•	Net earnings or loss per share

The Company calculates net earning or loss per share in accordance with ASC Topic 260 “Earnings per share”. Basic earning or loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted earning or loss per share is computed similar to basic earning or loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common stock equivalents had been issued and if the additional common shares were dilutive.

Table of Contents

BIONEXUS GENE LAB CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED MARCH 31, 2021

(Currency expressed in United States Dollars (“US$”))

(Unaudited)

•	Foreign currencies translation

Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transaction. Monetary assets and liabilities denominated in currencies other than the functional currency are translated into the functional currency using the applicable exchange rates at the balance sheet dates. The resulting exchange differences are recorded in the statement of operations.

The functional currency of the Company is the United States Dollars (“US$”) and the accompanying financial statements have been expressed in US$. In addition, the subsidiaries maintain its books and record in a local currency, Malaysian Ringgit (“MYR” or “RM”), which is functional currency as being the primary currency of the economic environment in which the subsidiaries operate.

In general, for consolidation purposes, assets and liabilities of its subsidiaries whose functional currency is not US$ are translated into US$, in accordance with ASC Topic 830-30, “Translation of Financial Statement”, using the exchange rate on the balance sheet date. Revenues and expenses are translated at average rates prevailing during the period. The gains and losses resulting from translation of financial statements of foreign subsidiary are recorded as a separate component of accumulated other comprehensive income.

Translation of amounts from MYR into US$1.00 has been made at the following exchange rates for the respective years:

	March 31, 2021		December 31, 2020

Year-end US$1 : MYR exchange rate		4.1460		4.0170

	January 1, 2021 to March 31, 2021		January 1, 2020 to March 31, 2020

3 months average US$1 : MYR exchange rate		4.0678		4.1820

•	Related parties

Parties, which can be a corporation or individual, are considered to be related if the Company has the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial and operating decisions. Companies are also considered to be related if they are subject to common control or common significant influence.

Table of Contents

BIONEXUS GENE LAB CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED MARCH 31, 2021

(Currency expressed in United States Dollars (“US$”))

(Unaudited)

•	Fair value of financial instruments

The carrying value of the Company’s financial instruments: cash and cash equivalents, trade receivable, deposits and other receivables, amount due to related parties and other payables approximate at their fair values because of the short-term nature of these financial instruments.

The Company also follows the guidance of the ASC Topic 820-10, “Fair Value Measurements and Disclosures” ("ASC 820-10"), with respect to financial assets and liabilities that are measured at fair value. ASC 820-10 establishes a three-tier fair value hierarchy that prioritizes the inputs used in measuring fair value as follows:

·	Level 1 : Observable inputs such as quoted prices in active markets;

·		Level 2 : Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and

·	Level 3 : Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions

As of March 31, 2021, and December 31, 2020, the Company did not have any nonfinancial assets and liabilities that are recognized or disclosed at fair value in the financial statements, at least annually, on a recurring basis, nor did the Company have any assets or liabilities measured at fair value on a non-recurring basis.

●	Recent accounting pronouncements

The Company has reviewed all recently issued, but not yet effective, accounting pronouncements and does not believe the future adoption of any such pronouncements may be expected to cause a material impact on its financial condition or the results of its operations.

NOTE 4 – TRADE RECEIVABLES

The Company has performed an analysis on all its trade receivables and determined that all amounts are collectible by the Company. As such, trade receivables are reflected as a current asset and no allowance for expected credit loss has been recorded as of March 31, 2021 and December, 31, 2020. The Company’s trade receivables consist of receivable from customers which are unrelated to the Company. The account receivables are non-interest bearing and is generally on 30 days to 90 days term.

Table of Contents

BIONEXUS GENE LAB CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED MARCH 31, 2021

(Currency expressed in United States Dollars (“US$”))

(Unaudited)

NOTE 5 - INCOME TAXES

The Company provides for income taxes under ASC 740, “Income Taxes. ASC 740 requires the use of an asset and liability approach in accounting for income taxes. Deferred tax assets and liabilities are recorded based on the differences between the financial statements and tax basis of assets and liabilities and the tax rates in effect when these differences are expected to reverse. It also requires the reduction of deferred tax assets by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.

Provision for income taxes consisted of the following:

United States of America

The Company is registered in the State of Wyoming and is subject to the tax laws of the United States of America.

Malaysia

Bionexus Gens Lab Sdn. Bhd. and Chemrex Corporation Sdn. Bhd. are subject to Malaysia Corporate Tax, which is charged at the statutory income tax rate range is 24% on its assessable income. Under the amendment of Income Tax Act 1967 by the Finance Act 2019 and with effect from year of assessment 2021, companies with paid-up capital of MYR2.5 million or less, and with annual business income of not more than RM50 million are subject to Small and Medium Enterprise Corporate Tax at 17% on chargeable income up to MYR600,000 except for companies with investment holding nature or companies does not have gross income from business sources are subject to corporate tax at 24% on chargeable income.

	As of
	March 31,			December 31,
	2021			2020
Tax Recoverable
Local	$	-		$	-
Foreign, representing Malaysia		(2,624	)		(2,190	)
Tax Recoverable		(2,624	)		(2,190	)

Income tax liabilities:
Local	$	-		$	-
Foreign, representing Malaysia		28,874			61,313
Income tax liabilities		28,874			61,313

Deferred tax liabilities:
Local	$	-		$	-
Foreign, representing Malaysia		1,813			1,872
Deferred tax liabilities		1,813			1,872
Total		28,063			60,995

Table of Contents

BIONEXUS GENE LAB CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED MARCH 31, 2021

(Currency expressed in United States Dollars (“US$”))

(Unaudited)

NOTE 6 –LEASE RIGHT OF USE ASSET AND LEASE LIABILITY

Operating lease right of use as follow:

	As of
	March 31,			December 31,
	2021			2020
Balance as of beginning of the year	$	62,529		$	23,542
Add: Addition of right of use assets		-			61,128
Less: accumulated amortization		(5,214	)		(22,587	)
Foreign translation differences		(1,568	)		446
Balance	$	55,747		$	62,529

Operating lease liability as follow:	As of
	March 31,			December 31,
	2021			2020
Balance as of beginning of the year	$	63,079		$	24,148
Add: Addition of lease liabilities		-			61,128
Less: gross repayment		(4,705	)		(26,036	)
Add: imputed interest		795			3,380
Foreign translation differences		(2,465	)		459
Balance as of end of the year		56,704			63,079
Less: lease liability current portion		(16,793	)		(20,702	)
Lease liability non-current portion	$	39,911		$	42,377

The amortization of the operating lease right of use asset for the three months’ period ended March 31, 2021 and the year ended December 31, 2020 were $2,637 and $10,816 respectively.

Other information:	As of
	March 31,			December 31,
	2021			2020
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flow from operating lease	$	6,375		$	38,931
Right of use assets obtained in exchange for operating lease liabilities		55,747			65,529
Remaining lease term for operating lease (years)		3.75			4
Weighted average discount rate for operating lease		5.40	%		5.40	%

Table of Contents

BIONEXUS GENE LAB CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED MARCH 31, 2021

(Currency expressed in United States Dollars (“US$”))

(Unaudited)

NOTE 7 - PROPERTY, PLANT AND EQUIPMENT

Property, plant and equipment consisted of the following:

	As of
	March 31,			December 31,
	2021			2020

Air conditioner	$	1,124		$	1,124
Computer and software		1,371			1,371
Equipment		43,010			42,830
Furniture and fittings		86,961			86,961
Lab equipment		284,822			284,822
Land and buildings		1,506,969			1,506,969
Motor vehicle		137,914			137,914
Office equipment		35,787			35,160
Renovation		107,414			107,414
Signboard		704			704
		2,206,074			2,205,269
(Less): Accumulated depreciation		(473,961	)		(441,541	)
Add: Foreign translation differences		(24,009	)		21,874
Property, plant and equipment, net	$	1,708,104		$	1,785,602

Depreciation expense for the three months’ period ended March 31, 2021 and 2020 were $10,622 and $10,278, respectively.

NOTE 8 – OTHER INVESTMENTS

	As of
	March 31,			December 31,
	2021			2020
As of beginning of the year	$	281,668		$	12,215
Acquisition of business under common control		-			147,882
Addition during the year		296,025			108,631
Disposal during the year		-			(34,923	)
Fair value gain		8,264			38,742
Foreign exchange translation		(14,348	)		9,121
As of end of the year	$	571,609		$	281,668

The other investments consist of investment in quoted and unquoted shares in Malaysia of $569,725 and $1,884 as at March 31, 2021 and December 31, 2020 were $279,724 and $1,944, respectively.

Table of Contents

BIONEXUS GENE LAB CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED MARCH 31, 2021

(Currency expressed in United States Dollars (“US$”))

(Unaudited)

NOTE 9 – TRADE PAYABLES

Trade payables are amounts billed to the Company by suppliers for goods and services in the ordinary course of business. All amounts have short-term repayment terms and vary by supplier.

NOTE 10 – FINANCE LEASE

The Company purchased motor vehicles under finance lease agreements with the effective interest rate 5.70% of per annum, with principal and interest payable monthly. The obligations under the finance lease are as follows:

	As of
	March 31,			December 31,
	2021			2020

Finance lease	$	54,440		$	63,703
Less: interest expense		(2,649	)		(3,363	)
Net present value of finance lease		51,791			60,340

Current portion		22,843			25,048
Non-current portion		28,948			35,292
Total	$	51,791		$	60,340

NOTE 11 – STOCK HOLDERS’ EQUITY

As at March 31, 2021, the Company issued and outstanding common stock is 171,218,152 shares.

NOTE 12 – SEGMENTED INFORMATION

At March 31, 2021, the Company (“BGLC”) operates in biochemical industry segment through its two Malaysian subsidiaries, BioNexus Malaysia and Chemrex.

Table of Contents

The corporate structure as at March 31, 2021 is depicted below:

For the quarter ended March 31, 2021, segmented (unaudited) revenue and net profit/(loss) (Currency expressed in United States Dollars (“US$”) are as follows:

	BioNexus Malaysia			Chemrex			Total			Consolidated with BGLC
	Three months ended March 31, 2021

REVENUE	$	97,363		$	3,351,796		$	3,449,159		$	3,449,159

COST OF REVENUE		(67,707	)		(2,798,887	)		(2,866,594	)		(2,866,594	)

GROSS PROFIT		29,656			552,909			582,565			582,565

OTHER INCOME		763			61,625			62,388			62,388

OPERATING EXPENSES
General and administrative		(22,511	)		(233,152	)		(255,663	)		(302,851	)

FINANCE COSTS		(1,207	)		(2,151	)		(3,358	)		(3,358	)

PROFIT BEFORE TAX		6,701			379,231			385,932			338,744

Tax expense:		0			0			0			0

NET PROFIT	$	6,701		$	379,231		$	385,932		$	338,744

Table of Contents

	BioNexus Malaysia			Chemrex			Total			Consolidated with BGLC
	Three months ended March 31, 2020

REVENUE	$	0		$	3,070,026		$	3,070,026		$	3,070,026

COST OF REVENUE		(12,992	)		(2,401,727	)		(2,414,719	)		(2,414,719	)

GROSS (LOSS)/PROFIT		(12,992	)		668,299			655,307			655,307

OTHER INCOME		4,745			741,896			746,641			746,641

OPERATING EXPENSES
General and administrative		(20,149	)		(290,635	)		(310,784	)		(328,418	)

FINANCE COSTS		(1,063	)		(1,963	)		(3,026	)		(3,026	)

(LOSS)/PROFIT BEFORE TAX		(29,459	)		1,117,597			1,088,138			1,070,504

Tax expense:		(860	)		0			(860	)		(860	)

NET (LOSS)/PROFIT	$	(30,319	)	$	1,117,597		$	1,087,278		$	1,069,644

	As Of March 31, 2021 and December 31, 2020
	Total Assets				Total Liabilities
	2021		2020		2021		2020

Bionexus (M)	$	816,893	$	902,552	$	711,549	$	800,610
Chemrex		8,894,730		9,008,245		2,976,336		3,283,814
TOTAL		9,711,623		9,910,797		3,687,885		4,084,424

Table of Contents

BIONEXUS GENE LAB CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED MARCH 31, 2021

(Currency expressed in United States Dollars (“US$”))

(Unaudited)

NOTE 13 - SUBSEQUENT EVENTS

In accordance with ASC Topic 855, “Subsequent Events”, which establishes general standards of accounting for and disclosure of events that occur after the balance sheet date but before financial statements are issued, the Company has evaluated all events or transactions that occurred after March 31, 2021 up through April 30, 2021 of these consolidated financial statements.

NOTE 14 – SIGNIFICANT EVENTS

On March 11, 2020, the World Health Organization declared the Coronavirus (“Covid-19”) outbreak to be a pandemic, which has caused severe global social and economic disruptions and uncertainties, including markets where the Company operates or intends to operate. The Company is actively monitoring and managing its operations to respond to these changes, the Company does not consider it practicable to provide any quantitative estimate on the potential impact it may have on the Company as the outbreak continue to evolve as of the date of this report.

NOTE 15 - CONCENTRATION OF RISKS

a) Major customers

During the period, the Company did not have any material recognizable major customers accounted for 10% or more of the Company’s revenue for the financial year ended Dec 31, 2020 and quarterly financial period ended March 31, 2021 and 2020.

b) Major suppliers

There were 3 major suppliers who accounted for 10% or more of the Company’s cost of revenue and their balance at the end of 1^st quarter ended March 31, 2021 are presented as below:

Major Suppliers	Purchases		Percentage of cost of revenue			Payable balance
(1st quarter ended March 31, 2021)
Singapore Highpolymer Chemical Products	$	776,469		27.09	%	$	1,324,528
Changzhou Pro-Tech Trade Co. Ltd	$	451,074		15.74	%	$	382,658
Luxchem Trading Sdn Bhd	$	404,056		14.09	%	$	404,056
	$	1,631,599		56.92	%	$	2,111,242

There were 3 major suppliers who accounted for 10% or more of the Company’s cost of revenue and their balance at the end of 1st quarter ended December 31, 2020 are presented as below:

Major Suppliers	Purchases		Percentage of cost of revenue			Payable balance
(Financial year ended Dec 31, 2020)
Singapore Highpolymer Chemical Products	$	2,090,090		21.62	%	$	1,031,417
Luxchem Trading Sdn Bhd	$	1,350,069		13.96	%	$	572,938
Changzhou Pro-Tech Trade Co. Ltd	$	1,319,232		13.64	%	$	335,215
	$	4,759,391		49.22	%	$	1,939,570

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

Forward-Looking Statements

Certain statements made in this quarterly report on Form 10-Q are “forward-looking statements” (within the meaning of the Private Securities Litigation Reform Act of 1995) in regard to the plans and objectives of management for future operations. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of the registrant to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. The forward-looking statements included herein are based on current expectations that involve numerous risks and uncertainties. The Company’s plans and objectives are based, in part, on assumptions involving the continued expansion of business. Assumptions relating to the foregoing involve judgments with respect to, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the control of the Company. Although the Company believes its assumptions underlying the forward-looking statements are reasonable, any of the assumptions could prove inaccurate and, therefore, there can be no assurance the forward-looking statements included in this quarterly report will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by the registrant or any other person that the objectives and plans of the registrant will be achieved.

Substantial risks exist with respect to an investment in the Company. These risks include but are not limited to, those factors discussed in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 30, 2021. More broadly, these factors include, but are not limited to:

•

We have limited operating history and limited business growth;

•

The efficacy of our blood screening process;

•

We may face product liability claims and we have no insurance to cover such claims; and

•

There are risks associated with our business operations in Malaysia, including enforcing judgements against our operating subsidiary and management.

The results of operations for BioNexus described below have been adversely impacted by the onset of the Covid-19 pandemic, which commenced in late December 2019 in Malaysia. We believe that most people are reluctant to visit hospitals and clinics for fear of transmission from other patients or medical staff. Since our RNA screening is administered at hospitals and clinics, our business has been adversely affected as a result. Furthermore, on March 18, 2020, the Malaysian government had declared Movement Control Order for the entire nation which restricted movement of all people except for those who were working for essential services. This order has been extended to June 7, 2021.

Table of Contents

Description of Business

We have two operating subsidiaries located in Malaysia, Bionexus Gene Lab Sdn. Bhd. (“Bionexus Malaysia”) and Chemrex Corporation Sdn. Bhd. (“Chemrex”).

BioNexus Malaysia is an emerging molecular diagnostics company focused on the application of functional genomics to enable early diagnosis and personalized health management. It was incorporated in the State of Wyoming on May 12, 2017. On August 23, 2017, we acquired all of the outstanding capital stock of BioNexus Malaysia, which was incorporated in Malaysia on April 7, 2015. BioNexus Malaysia owns algorithm software, technology and know-how related to the detection of common diseases through blood analysis which we use in our business.

Our corporate and principal office address of BioNexus Malaysia is Unit 02, Level 10, Tower B, Avenue 3, The Vertical Business Suite II, Bangar South, No. 8 Jalan Kerinchi, Kuala Lumpur, Malaysia., our lab is located at Lab 353, Chemical Science Centre, University Science Malaysia, George Town, Penang, Malaysia. We also have a blood collection center located at 1^st floor, Lifecare Medical Centre, Kuala Lumpur, Malaysia. Our telephone number is (+60) 1221-26512 and our web-site is www.bionexusgenelab.com.

Chemrex is a wholesaler of industrial chemicals for the manufacture of industrial, medical, appliance, aero, automotive, mechanical and electronic industries in Asia Pacific region. On December 31, 2020, we acquired all of the outstanding capital stock of Chemrex, which was incorporated in Malaysia on September 29, 2004.

Chemrex’s corporate offices and distribution and storage center is located at 4 Jalan CJ 1/6 Kawasan Perusahaan Cheras Jaya, Selangor, Malaysia. Its phone number is (+60) 1922-23815 and web-site is www.chemrex.com.my.

Our corporate structure is depicted below:

Table of Contents

BIONEXUS GENE LAB CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED MARCH 31, 2021

(Currency expressed in United States Dollars (“US$”))

(Unaudited)

Results of Operations

The following table sets forth key selected financial data for the three months ended March 31, 2021 and 2020.

	Three months ended
	March 31,
	2021			2020

REVENUE	$	3,449,159		$	3,070,026

COST OF REVENUE		(2,866,594	)		(2,414,719	)

GROSS PROFIT		590,235			655,307

OTHER INCOME		62,388			746,641

OPERATING EXPENSES
General and administrative		(302,851	)		(328,418	)

PROFIT FROM OPERATIONS		349,102			1,073,530

FINANCE COSTS		(3,358	)		(3,026	)

PROFIT BEFORE TAX		338,744			1,070,504

Tax expense		-			(860	)

NET PROFIT	$	338,744		$	1,069,644

Other comprehensive income:
Foreign currency loss		(208,468	)		(294,696	)

COMPREHENSIVE INCOME	$	130,276		$	774,948

Revenues. For the quarterly period ended March 31, 2021, we had revenue of $3,449,159 as compared to revenues of $3,070,026 for the quarterly period ended March 31, 2020, an increase of approximately 12% from the prior period. For the current quarterly period, Chemrex contributed 97% of total revenues compared to its contribution of 100% of total revenues for the quarterly period last year. Chemrex’s revenues increased from $3,070,026 in the prior quarter to $3,449,159 for the current quarter, an increase of 12.3%. The increase was due to the easing of the governmental movement control restrictions during the current periods allowing business sectors to resume operations. BioNexus had revenues of $97,363 for the current quarter compared with no revenues from the same quarterly period last year. BioNexus’ revenues for the current quarter resulted from sale of its cancers screening services to clinics and hospitals as the governmental movement control restrictions eased during the current quarter.

Table of Contents

Cost of revenues. For the quarterly period ended March 31, 2021, we incurred $2,866,594 in cost of revenues, as compared to $2,414,719 for the quarterly period ended March 31, 2020, an increase of approximately 18.7%. Of the total cost of revenues for the current period, Chemrex had incurred 98% of the total compared with the same period last year wherein Chemrex had incurred 99% of the total. The decrease in Chemrex’s cost of revenues for the current period was due to its increased revenues for the current period. The increase in BioNexus’ cost of revenues for the current period was due to its testing on blood samples of the heart attack patient with National Heart Centre (IJN) and the testing of newly bought Covid-19 screening kits which were imported from China and Korea.

Other Income. For the quarterly period ended March 31, 2021, we had other income of $62,388, as compared to $746,641 for the quarterly period ended March 31, 2020, a 1097% reduction from the prior quarterly period due gain on disposal of property $706,953 in the same quarter last year. We did not have a similar gain during the current quarterly period.

Operating Expenses. For the quarterly period ended March 31, 2021, we had an operating expense of $302,851 as compared to operating expenses of $328,418 for the quarterly period ended March 31, 2020, a decrease of approximately 8.4%. Operating expenses consists of general and administrative expenses which includes depreciation of fixed assets, employee compensation and benefits, professional fees and marketing and travel expenses. The decrease for the current quarterly period reflects the reduction of travel and marketing expenses which were replaced by video conferencing.

Profit from operations. We had a profit from operations of $342,102 quarterly period ended March 31, 2021 compared with a profit of $1,073,530 for the quarterly period ended March 31, 2020 for the reasons discussed above.

Income tax expense. For the quarterly period ended March 31, 2021, we had no income tax expense for the period as compared with $860 for the quarterly period ended March 31, 2020.

LIQUIDITY AND CAPITAL RESOURCES

As of March 31, 2021, we had working capital of $4,527,642 compared with working capital of $4,611,896 as of December 31, 2020. The decrease in working capital as of March 31, 2021 from December 31, 2020 is due principally to the reduction in cash used in our operations.

Table of Contents

Our primary uses of cash have been for operations. The main sources of cash have been from operational revenues and the private placement of our common stock. The following trends are reasonably likely to result in a material decrease in our liquidity over the near to long term:

	·	Addition of administrative and marketing personnel as the business grows,

	·	Development of a Company website,

	·	Increases in advertising and marketing in order to attempt to generate more revenues, and

	·	The cost of being a public company.

The Company believes that cash flow from operations together will be sufficient to sustain its current level of operations for at least the next 12 months of operations.

The following is a summary of the Company’s cash flows provided by (used in) operating, investing, and financing activities for the three months ended March 31, 2021 and 2020:

	Three months ended
	March 31,
	2021			2020
Foreign currency translation adjustment		(124,085	)		(190,829	)
Net Cash Generated from/(Used in) Operating Activities	$	115,428		$	(977,348	)
Net Cash /(Used in )/Generated from Investing Activities		(295,826	)		1,712,247
Net Cash Used in Financing Activities		(8,550	)		(6,399	)
Net Change in Cash and Cash Equivalents	$	(313,033	)	$	537,671

Operating Activities

During the three months ended March 31, 2021, the Company incurred a net profit of $338,744 which, after adjusting for amortization, depreciation, dividend income, fair value on investment, an increase in inventories, a reduction in trade receivables and deposits, a substantial reduction in trade payables, operating lease liabilities, resulted in net cash of $115,428 being generated from operating activities during the period. By comparison, during the three months ended March 31, 2020, the Company had a net profit of $1,069,644 which, after adjusting for amortization, depreciation, dividend income, gain on disposal of property, plant and equipment, a decrease in inventories, an increase in receivables and deposits, a substantial reduction in trade payables, operating lease liabilities, resulted in net cash of $977,348 being used in operating activities during the period.

Investing Activities

During the three months ended March 31, 2021, the Company had net cash of $295,826 used in investment activities. During the three months ended March 31, 2020, the Company had net cash from acquisition of business under common control and disposed of property, plant and equipment of $1,467,865, resulting in net cash generated from investment activities of $1,712,247.

Financing Activities

During the three months ended March 31, 2021, the Company a repayment of a finance lease resulting in net cash used in financing activities of $8,550. By comparison, during the three months ended March 31, 2020, the financing activities of $6,399.

Table of Contents

Summary of Significant Accounting Policies.

•	Basis of presentation

These accompanying financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”).

•	Basis of consolidation

•	Use of estimates

In preparing these financial statements, management makes estimates and assumptions that affect the reported amounts of assets and liabilities in the balance sheets and revenues and expenses during the years reported. Actual results may differ from these estimates.

•	Cash and cash equivalents

•	Plant and equipment

Plant and equipment are stated at cost less accumulated depreciation and accumulated impairment losses, if any. Depreciation is calculated on the straight-line basis to write off the cost over the following expected useful lives of the assets concerned. The principal annual rates used are as follows:

Categories				Principal Annual Rates
Air conditioner				20%
Buildings				2%
Computer and software				33%
Equipment				20%
Furniture and fittings				10% to 20%
Lab Equipment				10%
Motor vehicle				10% to 20%
Office equipment				20%
Renovation				10% to 20%
Signboard				10%

Fully depreciated plant and equipment are retained in the financial statements until they are no longer in use.

Table of Contents

•	Trade receivables

Trade receivables are recorded at the invoiced amount and do not bear interest. Management reviews the adequacy of the allowance for doubtful accounts on an ongoing basis, using historical collection trends and aging of receivables. Management also periodically evaluates individual customer’s financial condition, credit history, and the current economic conditions to make adjustments in the allowance when it is considered necessary. Trade balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote.

•	Inventories

•	Impairment of long-lived assets

•	Finance lease

Leases that transfer substantially all the rewards and risks of ownership to the lessee, other than legal title, are accounted for as finance leases. Substantially all of the risks or benefits of ownership are deemed to have been transferred if any one of the four criteria is met: (i) transfer of ownership to the lessee at the end of the lease term, (ii) the lease containing a bargain purchase option, (iii) the lease term exceeding 75% of the estimated economic life of the leased asset, (iv) the present value of the minimum lease payments exceeding 90% of the fair value. At the inception of a finance lease, the Company as the lessee records an asset and an obligation at an amount equal to the present value of the minimum lease payments. The leased asset is amortized over the shorter of the lease term or its estimated useful life if title does not transfer to the Company, while the leased asset is depreciated in accordance with the Company’s depreciation policy if the title is to eventually transfer to the Company. The periodic rent payments made during the lease term are allocated between a reduction in the obligation and interest element using the effective interest method in accordance with the provisions of ASC Topic 835-30, “Imputation of Interest”.

Table of Contents

•	Revenue recognition

Revenue recognized when it is probable that the economic benefits associated with the transaction will flow to the enterprise and the amount of the revenue can be measured reliably. Revenue is measured at the fair value of consideration received or receivable.

Sales of goods or rendering of services

An entity shall recognize revenue associated with the transaction by reference to the stage of completion of the transaction at the end of the reporting period. The outcome of a transaction can be estimated reliably when all the following conditions are satisfied: -

The amount of revenue can be measured reliably;

ii.

It is probable that the economic benefits associated with the transaction will flow to the entity;

iii.

The stage of completion of the transaction at the end of the reporting period can be measured reliably; and

iv.

The costs incurred for the transaction and the costs to complete the transaction can be measured reliably.

Interest income

Interest is recognized on receipt basis.

•	Cost of revenues

•	Shipping and handling fees

Shipping and handling fees, if billed to customers, are included in revenue. Shipping ang handling fees associated with inbound and outbound freight are expensed as incurred and included in selling and distribution expenses.

•	Comprehensive income

Table of Contents

•	Income tax expense

ASC 740 prescribes a comprehensive model for how companies should recognize, measure, present, and disclosed in their financial statements uncertain tax positions taken or expected to be taken on a tax return. Under ASC 740, tax positions must initially be recognized in the financial statements when it is more likely than not the position will be sustained upon examination by the tax; the present value of the minimum lease payments. The leased asset is amortized over the shorter of the lease term or its estimated useful life if title does not transfer to the Company, while the leased asset is depreciated in accordance with the Company’s depreciation policy if the title is to eventually transfer to the Company. The periodic rent payments made during the lease term are allocated between a reduction in the obligation and interest element using the effective interest method in accordance with the provisions of ASC Topic 835-30, “Imputation of Interest”.

Translation of amounts from the local currency of the Company into US$1 has been made at the following exchange rates for the respective years:

	March 31, 2021		December 31, 2020

Year-end US$1 : MYR exchange rate		4.1460		4.0170

	January 1, 2021 to March 31, 2021		January 1, 2020 to March 31, 2020

3 months average US$1 : MYR exchange rate		4.0678		4.1820

•	Related parties

•	Fair value of financial instruments

Table of Contents

·	Level 1: Observable inputs such as quoted prices in active markets;
·	Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and
·	Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions

•	Recent accounting pronouncements

Off Balance Sheet Arrangements

The Company does not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on the Company’s financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

Contractual Obligations

None.

Item 3. Quantitative and Qualitative Disclosures about Market Risk.

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, the Company is not required to provide information required by this Item.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

In connection with the preparation of this quarterly report, an evaluation was carried out by the Company’s management, with the participation of the principal executive officer and the principal financial officer, of the effectiveness of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act (“Exchange Act”) as of March 31, 2021. Disclosure controls and procedures are designed to ensure that information required to be disclosed in reports filed or submitted under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the Commission’s rules and forms, and that such information is accumulated and communicated to management, including the principal executive officer and the principal financial officer, to allow timely decisions regarding required disclosures.

Table of Contents

Based on that evaluation, the Company’s management concluded, as of the end of the period covered by this report, that the Company’s disclosure controls and procedures were not effective in recording, processing, summarizing, and reporting information required to be disclosed, within the time periods specified in the Commission’s rules and forms, and that such information was not accumulated and communicated to management, including the principal executive officer and the principal financial officer, to allow timely decisions regarding required disclosures.

Management’s Report on Internal Control over Financial Reporting

The management of the Company is responsible for establishing and maintaining adequate internal control over financial reporting. The Company’s internal control over financial reporting is a process, under the supervision of the principal executive officer and the principal financial officer, designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of the Company’s financial statements for external purposes in accordance with United States generally accepted accounting principles (GAAP). Internal control over financial reporting includes those policies and procedures that:

Pertain to the maintenance of records that is in reasonable detail accurately and fairly reflect the transactions and dispositions of the Company’s assets;

ii)

Provide reasonable assurance that transactions are recorded as necessary to permit preparation of the financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures are being made only in accordance with the authorizations of management and the board of directors; and

iii)

Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the Company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions or that the degree of compliance with the policies or procedures may deteriorate.

The Company’s management conducted an assessment of the effectiveness of our internal control over financial reporting as of March 31, 2021, based on criteria established in Internal Control – Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission, which assessment identified material weaknesses in internal control over financial reporting. A material weakness is a control deficiency, or a combination of deficiencies in internal control over financial reporting that creates a reasonable possibility that a material misstatement in annual or interim financial statements will not be prevented or detected on a timely basis. Since the assessment of the effectiveness of our internal control over financial reporting did identify a material weakness, management considers its internal control over financial reporting to be ineffective.

Management has concluded that our internal control over financial reporting had the following material deficiencies:

Table of Contents

We were unable to maintain segregation of duties within our business operations due to our reliance on a single individual fulfilling the role of sole officer and director.

ii)

Lack of a functioning audit committee due to a lack of a majority of independent members and a lack of a majority of outside directors on our Board of Directors, resulting in ineffective oversight in the establishment and monitoring of required internal controls and procedures.

While these control deficiencies did not result in any audit adjustments to our 2021 or 2020 interim or annual financial statements, it could have resulted in a material misstatement that might have been prevented or detected by a segregation of duties. Accordingly, we have determined that this control deficiency constitutes a material weakness.

To the extent reasonably possible, given our limited resources, our goal is, upon consummation of a merger with a private operating company, to separate the responsibilities of principal executive officer and principal financial officer, intending to rely on two or more individuals. We will also seek to expand our current board of directors to include additional individuals willing to perform directorial functions. Since the recited remedial actions will require that we hire or engage additional personnel, this material weakness may not be overcome in the near term due to our limited financial resources. Until such remedial actions can be realized, we will continue to rely on the advice of outside professionals and consultants.

This quarterly report does not include an attestation report of our registered public accounting firm regarding our internal controls over financial reporting. Management’s report was not subject to attestation by our registered public accounting firm pursuant to Section 404(c) of the Sarbanes-Oxley Act that permit us to provide only management’s report in this annual report.

Changes in Internal Controls over Financial Reporting

During the quarter ended March 31, 2021, there has been no change in internal control over financial reporting that has materially affected or is reasonably likely to materially affect our internal control over financial reporting.

Table of Contents

PART II OTHER INFORMATION

Item 1. Legal Proceedings.

There are presently no material pending legal proceedings to which the Company, any executive officer, any owner of record or beneficially of more than five percent of any class of voting securities is a party or as to which any of its property is subject, and no such proceedings are known to the Company to be threatened or contemplated against it.

Item 1A. Risk Factors.

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, the Company is not required to provide information required by this Item.

Item 2. Unregistered Sale of Equity Securities and Use of Proceeds.

None.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

Not applicable to our Company.

Item 5. Other Information.

During the fiscal quarter ended March 31, 2021 and in connection with our acquisition of Chemrex, Wei Li Leong, our Chief Financial Officer, received 2,000,000 shares of our common stock from the Chemrex shareholders. Each Chemrex shareholder contributed ratably to the total amount of shares received by Ms. Leong. Ms. Leong provided various accounting and financial services to Chemrex and its shareholders in connection with the acquisition transaction with the Company which occurred on December 31, 2020. As a result, Ms. Leong now owns 4,797,709 shares of our common stock (or 2.8% of the total issued and outstanding shares of common stock).

On April 28, 20021, BioNexus entered into a Memorandum of Understanding with Universiti Tunku Abdul Rahman, one of the largest private universities in Malaysia. The parties will seek to collaborate and exchange ideas specifically in the advancement of Ribonucleic Acid (RNA) research into clinical application on cancers, inflammatory diseases, osteoarthritis, mental disorders, cardiovascular disease, Covid-19 and other screening services.

Table of Contents

Item 6. Exhibits.

Exhibit		Description
31.1		Certification of the Company’s Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*

31.2		Certification of the Company’s Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*

32.1		Certification of the Company’s Principal Executive Officer and Principal Financial pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002+

101.INS		XBRL INSTANCE DOCUMENT*

101.SCH		XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT*

101.CAL		XBRL TAXONOMY CALCULATION LINKBASE DOCUMENT*

101.DEF		XBRL TAXONOMY DEFINITION LINKBASE DOCUMENT*

101.LAB		XBRL TAXONOMY LABEL LINKBASE DOCUMENT*

101.PRE		XBRL TAXONOMY PRESENTATION LINKBASE DOCUMENT*

__________

+ In accordance with SEC Release 33-8238, Exhibit 32.1 is being furnished and not filed.

*	Filed herewith.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

BIONEXUS GENE LAB CORPORATION

/s/ Chan Chong Wong
Chan Chong Wong
Chief Executive Officer and Director
(Principal Executive Officer)

/s/ Wei Li Leong
Wei Li Leong
Chief Financial Officer
(Principal Financial and Accounting Officer)

May 17, 2021

BioNexus Gene Lab Corp - FORM 10-Q - May 18, 2021

Attached files

BioNexus Gene Lab Corp Reports